How long does Spravato stay in your system?

The clinical pharmacology section of the FDA label (revised 04/2025) is the source for the following.

Absorption. After nasal spray administration, mean absolute bioavailability is about 48%. Time to maximum esketamine plasma concentration is typically 20 to 40 minutes after the last nasal spray in the dosing sequence.

Distribution and decline. Esketamine exposure increases with dose from 28 mg to 84 mg. No accumulation in plasma was observed with twice-weekly administration. The decline in plasma concentrations is biphasic: rapid decline for the initial 2 to 4 hours, then a slower terminal phase with a mean terminal half-life (t½) of 7 to 12 hours.

Metabolism. Esketamine is primarily metabolized to noresketamine via cytochrome P450 enzymes, chiefly CYP2B6 and CYP3A4, and to a lesser extent CYP2C9 and CYP2C19. Noresketamine is active at the same receptor with less affinity; its plasma decline is also biphasic, with a mean terminal half-life of about 8 hours. Less than 1% of a nasal dose is excreted as unchanged drug in urine; metabolites are recovered primarily in urine.

Half-life vs "fully cleared". A terminal half-life of 7–12 hours means that after that many hours, roughly half of the remaining drug in the terminal phase is gone — not that the drug vanishes in one half-life. A rough population-level heuristic is on the order of five half-lives for practical elimination from plasma (roughly 1.5–2.5 days for that terminal range). Individual factors (dose, hepatic function, other medications affecting CYP enzymes) move this. The label notes there is no clinical experience with Spravato in patients on renal dialysis or with severe (Child-Pugh class C) hepatic impairment.

Felt effects end sooner than full elimination. The REMS two-hour monitoring window is built around acute sedation, dissociation, and blood-pressure effects — not around waiting for complete pharmacokinetic clearance. People often feel largely recovered while residual drug is still measurable. That is normal pharmacology, not a contradiction.

People also search "does Spravato show up on a drug test." The careful answer, anchored to the label's pharmacokinetics rather than lab-vendor marketing:

Esketamine is not a routine immunoassay target the way THC, opioids, or amphetamines often are. A standard workplace panel is not designed around prescribed esketamine. That does not mean detection is impossible. Ketamine and esketamine can be detected when a test is built or ordered to look for them (specific assays, expanded panels, forensic or clinical toxicology testing).

What matters practically. If testing is a concern — employment screening, custody, a pain-management agreement, athletic testing — disclose the legitimate prescription to whoever ordered the test and to the Medical Review Officer when one is involved. Bring the prescription context (REMS-certified administration, dates of dosing). Hiding a prescribed Schedule III medication is a worse plan than documenting it.

No timing advice. This page will not advise how to "beat," delay, or time a test around a session. Clearance estimates above are educational pharmacology, not a protocol for evasion.

If a test result creates a problem despite a valid prescription, the resolution path runs through the ordering clinician, the MRO, and your prescriber — not through a consumer website.

As of the FDA label revised 04/2025:

• Generic / chemical identity. Spravato is esketamine nasal spray — the S-enantiomer of racemic ketamine — a Schedule III controlled substance.
• Drug class / target. Esketamine is a non-selective, non-competitive antagonist of the NMDA receptor (an ionotropic glutamate receptor).
• Antidepressant mechanism. The label states that the mechanism by which esketamine exerts its antidepressant effect is unknown. The major circulating metabolite, noresketamine, has activity at the same receptor with less affinity. Do not treat popular "rewires the brain" marketing language as label science.

This is enough to answer "what does it do," "what drug class is it," and "is it the same as ketamine" without overclaiming. How Spravato differs from off-label IV ketamine clinics is covered on the find-a-provider page.

Why you still cannot drive even though clearance is relatively fast. The driving restriction is a label safety instruction about sedation, dissociation, and impaired ability to drive after dosing — not a stopwatch set to terminal half-life. The label instructs that patients must not drive or operate machinery until the next day after restful sleep. Feeling subjectively okay at two hours does not lift that instruction.

Pair this page with the session guide. What to expect covers the hour-by-hour visit and discharge rules. Side effects covers what people commonly feel and when to report problems. Pharmacokinetics explain the blood-level clock; they do not replace either page.

Planning. Treat dosing days as non-driving, low-demand days. Arrange the ride in advance for every session during induction (twice weekly for the first four weeks under the usual schedule). That logistical fact is usually harder than the half-life number.